Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Earnings Data
Report Date
Apr 30, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.03Same Quarter Last Year
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: revenue above guidance in Q4, accelerating volumes in key products (MyRisk, Prolaris, GeneSight), profitable Q4 results and strong cash generation, plus a robust product pipeline and reaffirmed 2026 guidance. Key challenges include a material UnitedHealthcare headwind for GeneSight, prenatal order-system disruption and near-term reimbursement uncertainty for MRD; management presented concrete mitigation actions, cautious commercialization plans for MRD, and targeted investments to accelerate growth. On balance, the positive operational and product-development progress and reaffirmed guidance outweigh the identifiable near-term headwinds.Company Guidance
Quarterly and Annual Revenue Above Expectations
Q4 2025 revenue of $209.8M (CEO rounded to $210M) came in above the high end of the preannounced range. Full year 2025 revenue was $824.5M.
Strong Test Volume and Provider Reach
Delivered ~382,000 test results in Q4 and over 1.5 million test reports for the full year 2025, serving more than 55,000 health care providers.
Hereditary Cancer (MyRisk) Volume Growth
MyRisk oncology volume gains: 14% year-over-year growth in the affected market and 11% year-over-year growth in the unaffected market; hereditary cancer testing grew 9% in Q4 and 7% for full year 2025.
Prolaris Momentum
Prolaris revenue accelerated to 16% year-over-year growth in Q4, driven by 12% test volume growth year-over-year after recent commercial investments.
GeneSight Recovery and Provider Expansion
GeneSight volume grew 9% year-over-year in Q4, revenue of $36.6M for the quarter, and a record >38,000 ordering clinicians in Q4; secured positive coverage policies across 12 payers (including Medi-Cal) in 2025.
Profitability and Cash Generation
Q4 adjusted gross margin ~70% (70% reported), adjusted EBITDA $14.3M, adjusted EPS $0.04, and adjusted operating cash flow $17.9M; maintained access to $225M in capital.
Robust Product and Commercial Roadmap with Confirmed Guidance
Launched expanded MyRisk panel (Q4); Prolaris AI-enhanced test planned for Q2 2026; Precise MRD alpha launch for breast cancer starting next week (select centers); FirstGene analytical validation published with commercial launch planned H2 2026. Reaffirmed full year 2026 guidance: revenue $860–$880M, adjusted gross margin 68–69%, adjusted EBITDA $37–$49M. Q1 2026 revenue guidance $200–$203M (2–4% growth).
MYGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MYGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 23, 2026 | $4.38 | $4.43 | +1.14% |
Nov 03, 2025 | $8.18 | $6.46 | -21.03% |
Aug 05, 2025 | $3.87 | $5.67 | +46.51% |
May 06, 2025 | $7.27 | $4.27 | -41.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Myriad Genetics (MYGN) report earnings?
Myriad Genetics (MYGN) is schdueled to report earning on Apr 30, 2026, TBA (Confirmed).
What is Myriad Genetics (MYGN) earnings time?
Myriad Genetics (MYGN) earnings time is at Apr 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MYGN EPS forecast?
MYGN EPS forecast for the fiscal quarter 2026 (Q1) is -0.07.